LPCN NASDAQ
Lipocine Inc.
1W: -2.4%
1M: -13.1%
3M: -17.0%
YTD: -74.4%
1Y: -31.0%
3Y: -29.3%
5Y: -89.0%
$2.05
-0.02 (-0.97%)
Weekly Expected Move ±5.4%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
0.00
Neutral
0 bullish
0 neutral
0 bearish
Articles (24h)
0
No articles in the last 24 hours
0.90
Bullish
2 bullish
0 neutral
0 bearish
Articles (7d)
2
Daily Sentiment (7 Days)
Articles (27)
Lipocine (NASDAQ:LPCN) Director John Higuchi Acquires 15,970 Shares of Stock
Lipocine (NASDAQ:LPCN) Director John Higuchi Buys 9,037 Shares of Stock
Lipocine (LPCN) Upgraded to Buy: What Does It Mean for the Stock?
Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026
Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
Lipocine (NASDAQ:LPCN) Shares Cross Below 200-Day Moving Average – Should You Sell?
John Higuchi Buys 40,000 Shares of Lipocine (NASDAQ:LPCN) Stock
HC Wainwright Forecasts Lipocine’s Q1 Earnings (NASDAQ:LPCN)
Lipocine (NASDAQ:LPCN) CEO Mahesh Patel Acquires 25,000 Shares of Stock
Lipocine (NASDAQ:LPCN) Director John Higuchi Purchases 123,000 Shares of Stock
What's Going On With Carvana Stock Monday?
What's Going On With Lipocine Stock On Monday?
This Carvana Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Monday
Lipocine Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
Crude Oil Rises Sharply; Acuity Shares Fall After Q2 Results
12 Health Care Stocks Moving In Thursday's Intraday Session
Lipocine Stock Plunges After LPCN 1154 Misses Phase 3 Primary Endpoint
Nasdaq Down 1%; US Initial Jobless Claims Fall
12 Health Care Stocks Moving In Tuesday's After-Market Session
Lipocine Announces Financial Results for the Full Year Ended December 31, 2025
Lipocine (LPCN) Soars 5.5%: Is Further Upside Left in the Stock?
Lipocine Announces Completion of Enrollment and Dosing in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine Reports Encouraging Progress Post Second Interim Safety Review in Phase 3 Trial of LPCN 1154 in Postpartum Depression (PPD)
Lipocine's PPD Phase 3 Study (LPCN 1154) Hits 80% Enrollment Milestone